38 Moreover, XL413 was found to collaborate with mTOR inhibitor to drastically inhibit HCC growth by blocking feedback re-activation of mTOR signaling, delivering so called “one-two-punch” strategy. In another study, XL413 was implied to potentiate ATR-CHK1 signaling inhibition in HCC.38 However, the therapeutic efficacy of combining DDK inhibitor and immune checkpoint blockade has not yet been investigated so far. This evidence concerns the gene MTOR and hepatocellular carcinoma.